



TREATING ITP:

Working Together to Improve Outcomes



CLINICAL COMPANION

OVERVIEW OF MANAGEMENT OPTIONS FOR ITP^{1,2}




1. **REDUCE** antiplatelet antibody production
2. **REDUCE** platelet removal
3. **INCREASE** platelet production

BAFF = B-cell activating factor; BTK = bruton tyrosine kinase; CXCR5 = chemokine receptor type 5; FcRn = neonatal fragment crystallizable; IVIG = Intravenous immunoglobulin; TPO-RA = thrombopoietin receptor agonists.


TREATING ITP:

Working Together to Improve Outcomes




CLINICAL COMPANION

CLINICAL ALGORITHM³




TREATING ITP:

Working Together to Improve Outcomes




CLINICAL COMPANION

EFFICACY OF CURRENT MANAGEMENT OPTIONS^{3,4}




SAFETY OF CURRENT MANAGEMENT OPTIONS^{3,4}



TREATING ITP:

Working Together to Improve Outcomes



CLINICAL COMPANION

COMPLEXITY OF ITP TREATMENT DECISIONS⁵⁻⁸

- Multiple second-line treatment options available, each with different benefits and risks
- Lack of comparative trials between treatments
- Variability in how patients respond to and tolerate different therapies

UNMET PATIENT NEEDS⁵⁻¹⁰

Diagnostic Tools:

- Reliable diagnostic tests
- Biomarkers to calculate risk and guide treatment decisions

QoL Improvements:


- Better management of fatigue
- Addressing cognitive impairment

Treatment Options:

- Improved side effect profiles and rapid response
- Refractory patients need better options for therapy
- Treatments that induce long-term remission without need for ongoing therapy
- Targeted therapies that address the various underlying mechanisms of cITP
- Studies on combination therapies

TREATING ITP:

Working Together to Improve Outcomes



CLINICAL COMPANION

FACTORS INFLUENCING TREATMENT INDICATION AND CHOICE OF THERAPY^{5,9,11-13}

Patient-related Factors

- Patient characteristics
- Concomitant medication
- Patient preference
- Comorbidities
- Compliance
- Lifestyle/work
- Sports

External Factors

- Financial restrictions
- Regulatory restrictions
- Guidelines
- Availability of treatment
- Physician preference

Treatment-related Factors

- Response
- Tolerance
- Schedule

Disease-related Factors

- Risk of bleeding
- Platelet count
- Phase of disease
- Symptoms

TREATING ITP:

Working Together to Improve Outcomes



CLINICAL COMPANION

PDSA RESOURCES

[ITP in Adults: Frequently Asked Questions](#)

[The Role and Function of Platelets in ITP](#)

[ITP Natural History Study Patient Registry](#)

[Health Insurance and Assistance Programs for ITP Patients](#)

REFERENCES

1. Audia S, Mahévas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B. [Immune thrombocytopenia: recent advances in pathogenesis and treatments](#). *Hemasphere*. 2021;5(6):e574.
2. Singh A, Uzun G, Bakchoul T. [Primary immune thrombocytopenia: novel insights into pathophysiology and disease management](#). *J Clin Med*. 2021;10(4):789.
3. Ghanima W, Gernsheimer T, Kuter DJ. [How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment](#). *Blood*. 2021;137(20):2736-2744.
4. Cooper N, Ghanima W. [Immune Thrombocytopenia](#). *N Engl J Med*. 2019;381(10):945-955.
5. Mingot-Castellano ME, Bastida JM, Caballero-Navarro G, et al. [Novel Therapies to Address Unmet Needs in ITP](#). *Pharmaceuticals (Basel)*. 2022;15(7):779.
6. Provan D. VJHemOnc. Accessed August 29, 2024. <https://www.youtube.com/watch?v=Muo8tGOsCv8&t=1s>
7. Gresele P. VJHemOnc. Accessed August 29, 2024. <https://www.youtube.com/watch?v=8R2AUBuFWno>
8. Grace RF, Despotovic JM, Bennett CM, et al. [Physician decision making in selection of second-line treatments in immune thrombocytopenia in children](#). *Am J Hematol*. 2018;93(7):882-888.
9. Neunert C, Terrell DR, Arnold DM, et al. [American Society of Hematology 2019 guidelines for immune thrombocytopenia](#). *Blood Adv*. 2019;3(23):3829-3866.
10. ITP Support Association. The New ITP Discussion Guide. Accessed October 4, 2024. <https://itpsupport.org.uk/the-new-itp-discussion-guide/>
11. Liu XG, Hou Y, Hou M. [How we treat primary immune thrombocytopenia in adults](#). *J Hematol Oncol*. 2023;16(1):4.
12. Matzdorff A, Meyer O, Ostermann H, et al. [Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI](#). *Oncol Res Treat*. 2018;41 Suppl 5:1-30.
13. Pietras NM, Gupta N, Justiz Vaillant AA, et al. Immune Thrombocytopenia. [Updated 2024 May 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562282/>